Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review

Siamaque Kazem, Emma Charlotte Linssen, Susan Gibbs

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Understanding skin metabolism is important when considering drug discovery and safety assessment. This review compares xenobiotic skin metabolism in ex vivo skin to reconstructed human skin and reconstructed human epidermis models, concentrating on phase I and phase II enzymes. Reports on phase I enzymes are more abundant than for phase II enzymes with mRNA and protein expression far more reported than enzyme activity. Almost all of the xenobiotic metabolizing enzymes detected in human skin are also present in liver. However, in general the relative levels are lower in skin than in liver and fewer enzymes are reported.

Original languageEnglish
JournalDrug Discovery Today
Volume24
Early online date6 Jun 2019
DOIs
Publication statusPublished - 1 Sep 2019

Cite this

@article{c4d3dfe183804d04a0f6aad7496752e6,
title = "Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review",
abstract = "Understanding skin metabolism is important when considering drug discovery and safety assessment. This review compares xenobiotic skin metabolism in ex vivo skin to reconstructed human skin and reconstructed human epidermis models, concentrating on phase I and phase II enzymes. Reports on phase I enzymes are more abundant than for phase II enzymes with mRNA and protein expression far more reported than enzyme activity. Almost all of the xenobiotic metabolizing enzymes detected in human skin are also present in liver. However, in general the relative levels are lower in skin than in liver and fewer enzymes are reported.",
author = "Siamaque Kazem and Linssen, {Emma Charlotte} and Susan Gibbs",
note = "Copyright {\circledC} 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.drudis.2019.06.002",
language = "English",
volume = "24",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",

}

Skin metabolism phase I and phase II enzymes in native and reconstructed human skin : a short review. / Kazem, Siamaque; Linssen, Emma Charlotte; Gibbs, Susan.

In: Drug Discovery Today, Vol. 24, 01.09.2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Skin metabolism phase I and phase II enzymes in native and reconstructed human skin

T2 - a short review

AU - Kazem, Siamaque

AU - Linssen, Emma Charlotte

AU - Gibbs, Susan

N1 - Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Understanding skin metabolism is important when considering drug discovery and safety assessment. This review compares xenobiotic skin metabolism in ex vivo skin to reconstructed human skin and reconstructed human epidermis models, concentrating on phase I and phase II enzymes. Reports on phase I enzymes are more abundant than for phase II enzymes with mRNA and protein expression far more reported than enzyme activity. Almost all of the xenobiotic metabolizing enzymes detected in human skin are also present in liver. However, in general the relative levels are lower in skin than in liver and fewer enzymes are reported.

AB - Understanding skin metabolism is important when considering drug discovery and safety assessment. This review compares xenobiotic skin metabolism in ex vivo skin to reconstructed human skin and reconstructed human epidermis models, concentrating on phase I and phase II enzymes. Reports on phase I enzymes are more abundant than for phase II enzymes with mRNA and protein expression far more reported than enzyme activity. Almost all of the xenobiotic metabolizing enzymes detected in human skin are also present in liver. However, in general the relative levels are lower in skin than in liver and fewer enzymes are reported.

UR - http://www.scopus.com/inward/record.url?scp=85067278717&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.06.002

DO - 10.1016/j.drudis.2019.06.002

M3 - Review article

VL - 24

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -